Madam Therapeutics

SAAP-148 gel for chronic wounds

Our skin flora contains billions of bacteria, of which the vast majority protects our skin. A good bacterial balance is necessary to maintain a healthy skin. Disruption of this balance can lead to, or aggravate, skin problems. No other bacterium causes more infections than Staphylococcus aureus. This bacterium is often found on the skin of people and animals. It can lead to serious (internal) infections and inflammation of the skin.

Staphylococcus aureus presents itself mainly on the skin, in the nose and hair, the armpits hands and perineum. A person’s immune system can help keep these bacteria under control, but when the immune system is weakened or suppressed, or the skin barrier is not intact, Staphylococcus aureus bacteria can cause infections.

Over the last 2 years, Madam Therapeutics has focused mostly on treatment and prevention of chronic wounds as the first clinical therapeutic indication for which we target our lead peptides SAAP-148. We have first chosen to focus on diabetic foot ulcers. With the data generated in our burn wound program in mind, we see this therapeutic indication as a logical next step that has a high chance of success.

The treatment and care of chronic wounds may be an not so glamorous aspect of medical practice, but for both the patient and the society, the resulting morbidity and cost are considerable. Indeed much of the medical establishment, whether through lack of confidence, training, interest, or remunerative potential, continues to perceive this to be under the province of someone else.

With the population advancing in age, increasing in weight and with the resultant comorbidities of diabetes and venous insufficiency, an increase in the number of patients with chronic wounds has been reported. It has been estimated that approximately 1% of the population will develop leg ulceration in the course of their lifetime. In the United States alone, chronic wounds affect 3 million to 6 million patients and treating these wounds costs an estimated $5 billion to $10 billion each year.

Of particular concern is the increase in the number of patients who have been insufficiently treated for their chronic wounds over protracted courses. SAAP-148 gel combines unprecedented potency with robustness against antimicrobial resistance development. These characteristics make SAAP-148 highly promising for the treatment of chronic wounds, allowing focusing on chronic antimicrobial therapy for the management of venous, arterial, diabetic, and pressure ulcers without any fear for resistance development.

stop-presssure-ulcers